Previous close | 402.20 |
Open | 401.50 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 396.40 - 404.10 |
52-week range | 396.40 - 767.40 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
Strategic collaboration agreement to commercialize Simris’ novel Antibody-Drug Conjugate (ADC) payload platformSimris grants Lonza, as its Contract Development & Manufacturing Organization (CDMO) partner, the global exclusive rights to offer its ADC technology to biopharmaceutical companiesSimris will promote Lonza as its exclusive CDMO partner to customers interested in licensing its technology Stockholm, Sweden, March 06, 2023 (GLOBE NEWSWIRE) -- Simris Alg AB (publ), a European biologics comp